{"entity":{"id":"nct07441174","kind":"trial","name":"IN10018 in Combination With RNK08954 for the Treatment of KRASG12D Mutation-Positive Locally Advanced or Metastatic Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of IN10018 in advanced solid tumours, run by InxMed (Shanghai) Co., Ltd., now recruiting.","summary":"IN10018 in Combination With RNK08954 for the Treatment of KRASG12D Mutation-Positive Locally Advanced or Metastatic Solid Tumors is a phase 1/2 interventional study registered as NCT07441174 by InxMed (Shanghai) Co., Ltd., with 92 participants planned, started 2026-02-28 and due to reach its primary completion in 2031-02-28. Interventions recorded: IN10018 in combination with RNK08954.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07441174","url":"https://clinicaltrials.gov/study/NCT07441174"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["in10018"],"companies":["ranok-therapeutics-hangzhou"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07441174","phase":"1/2","setting":"A Multicenter, Open-Label, Phase Ib/II Clinical Trial of IN10018 in Combination With RNK08954 for the Treatment of KRASG12D Mutation-Positive Locally Advanced or Metastatic Solid Tumors","sponsor":"InxMed (Shanghai) Co., Ltd.","enrolled":92,"outcomes":[]},"route":"/trials/nct07441174/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"drug":[{"id":"in10018","kind":"drug","name":"IN10018","route":"/drugs/in10018/"}],"company":[{"id":"ranok-therapeutics-hangzhou","kind":"company","name":"Ranok Therapeutics (Hangzhou)","route":"/companies/ranok-therapeutics-hangzhou/"}]}}